RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Theratechnologies Establishes New At-The-Market FacilityThat is a risk but surely they will not go down that path again. When nearly every other company is able to get its share price higher in today's market without having to be taken to the cleaners by institutional investors on the prowl for stupid management teams and boards willing to sell at ultra low prices, it would be quite devastating to see TH be a two time loser on that front. And I don't think they are that stupid.
But we know they have willfully misled us previously (CEO said they would not sell at such low prices before the OO). So, there is always a chance something is amiss with the cancer trial and they are allowing investors to feel good about the cancer prospects despite this. If that were to be the case (that they already know the cancer results are not going to cut it, or that the risk of a bad outcome is higher than we realize based on what they have shared so far) then selling shares here might make sense as the share price would fall if cancer was a dud. So, perhaps we will get a very good idea of what they really think about cancer by how they use this new facility. Unfortunately, the timing of the situation is such that we may not know what they have done with the facility until the cancer results are out.
So, there is certainly room for worriers to worry about this. But, despite management's past misleading statements around share offerings, I struggle to see how they could go that route again. They would lose all credibility for a very long time and they don't have much to start with.
archeo753 wrote: My first thought was that Cantor might have some clients that want shares at today's price and don't want to drive up the share price by aquiring in the open market. TH could release these ATM shares until they get their fill therefore dilluting legacy shareholders at what we all see as a discount to what the TH should be selling for. Glad to see others here have more positive views of the ATM stategy.